BPC 157

Body Protection Compound 157 upregulates the VEGFR2-eNOS pathway, accelerates angiogenesis, modulates NO signalling, and influences dopaminergic and serotoninergic systems. It also stimulates expression of growth-hormone receptor in tendon and ligament fibroblasts.

• Accelerated tendon-to-bone and tendon-to-tendon healing in animal models
• Protection of the gastric and intestinal mucosa
• Improved blood-vessel formation around injured tissue
• Modulation of inflammatory cytokines

Research range: 200-500 mcg subcutaneously near the area of interest, 1-2x daily for 4-6 weeks. Oral arginate salt has also been studied.

Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.

• BPC 157 and the central nervous system

  Frontiers in Pharmacology · 2022

  Review of >100 pre-clinical studies showing systemic regenerative effects.

• BPC 157 accelerates Achilles tendon healing in rats

  Journal of Orthopaedic Research · 2010

  Significantly improved tensile strength and collagen organisation.

• No serious adverse events reported in published animal work
• Limited controlled human trials
• Avoid concurrent use with active malignancy due to pro-angiogenic effect

For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.